To improve response to inhibitors targeting RAS, RAF, MEK, and MAPK, strategies such as the combination of MEK inhibitors with PI3K/Akt42,43 and EGFR44 inhibitors have been explored in the context of breast cancer. Here, MAP2K7 is linked to breast carcinoma.